Unveiling the intricacies of chronic kidney disease: From ocular manifestations to therapeutic frontiers.
chronic kidney disease
end‐stage kidney disease
glaucoma
imaging modalities
ocular manifestations
retinopathy
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
26 Sep 2024
26 Sep 2024
Historique:
received:
16
05
2024
accepted:
15
09
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
27
9
2024
Statut:
aheadofprint
Résumé
Shared anatomical, histological and physiological pathways between the kidney and the eye are well documented, demonstrating that ocular manifestations serve as valuable prognostic indicators in chronic kidney disease (CKD), providing insights into disease severity and progression. Through non-invasive imaging modalities such as retinal fundus photography, early retinal microvascular alterations indicative of CKD progression can be detected, enabling timely intervention and risk stratification. However, the conclusions drawn from the review primarily demonstrate a strong or independent association between glaucoma or retinopathy and CKD. Multiple shared pathophysiological events have been implicated in the pathogenesis in the alterations at eye and kidney including renin-angiotensin-aldosterone system. Patients with CKD are more likely to experience glaucoma, age-related macular degeneration, cataracts, uremic optic neuropathy and retinopathy. To establish the role of ocular manifestations in predicting CKD progression, it is crucial to address the limitations of correlation and explore the underlying causality with further research on common disease pathogenesis. Additionally, specific methods for risk stratification based on retinal changes, the effectiveness of timely interventions, and the development of predictive tools combining ocular and renal data are of utmost importance research topics to enlighten the bidirectional causality.
Sections du résumé
BACKGROUND
BACKGROUND
Shared anatomical, histological and physiological pathways between the kidney and the eye are well documented, demonstrating that ocular manifestations serve as valuable prognostic indicators in chronic kidney disease (CKD), providing insights into disease severity and progression. Through non-invasive imaging modalities such as retinal fundus photography, early retinal microvascular alterations indicative of CKD progression can be detected, enabling timely intervention and risk stratification. However, the conclusions drawn from the review primarily demonstrate a strong or independent association between glaucoma or retinopathy and CKD.
RESULTS AND CONCLUSION
CONCLUSIONS
Multiple shared pathophysiological events have been implicated in the pathogenesis in the alterations at eye and kidney including renin-angiotensin-aldosterone system. Patients with CKD are more likely to experience glaucoma, age-related macular degeneration, cataracts, uremic optic neuropathy and retinopathy. To establish the role of ocular manifestations in predicting CKD progression, it is crucial to address the limitations of correlation and explore the underlying causality with further research on common disease pathogenesis. Additionally, specific methods for risk stratification based on retinal changes, the effectiveness of timely interventions, and the development of predictive tools combining ocular and renal data are of utmost importance research topics to enlighten the bidirectional causality.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14324Informations de copyright
© 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Stevens LA, Viswanathan G, Weiner DE. Chronic kidney disease and end‐stage renal disease in the elderly population: current prevalence, future projections, and clinical significance. Adv Chronic Kidney Dis. 2010;17(4):293‐301.
Bello AK, Okpechi IG, Levin A, et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024;12(3):e382‐e395.
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7‐11.
United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health; 2022.
Zoccali C, Vanholder R, Massy ZA, et al. The systemic nature of CKD. Nat Rev Nephrol. 2017;13(6):344‐358.
Wong CW, Wong TY, Cheng CY, Sabanayagam C. Kidney and eye diseases: common risk factors, etiological mechanisms, and pathways. Kidney Int. 2014;85(6):1290‐1302.
Mullaem G, Rosner MH. Ocular problems in the patient with end‐stage renal disease. Semin Dial. 2012;25(4):403‐407.
Farrah TE, Dhillon B, Keane PA, Webb DJ, Dhaun N. The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons. Kidney Int. 2020;98(2):323‐342.
Farrah TE, Pugh D, Chapman FA, et al. Choroidal and retinal thinning in chronic kidney disease independently associate with eGFR decline and are modifiable with treatment. Nat Commun. 2023;14(1):7720.
Booij JC, Baas DC, Beisekeeva J, Gorgels TG, Bergen AA. The dynamic nature of Bruch's membrane. Prog Retin Eye Res. 2010;29(1):1‐18.
Boutaud A, Borza DB, Bondar O, et al. Type IV collagen of the glomerular basement membrane. Evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains. J Biol Chem. 2000;275(39):30716‐30724.
McAdoo SP, Pusey CD. Anti‐glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12(7):1162‐1172.
Savige J, Sheth S, Leys A, Nicholson A, Mack HG, Colville D. Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol. 2015;10(4):703‐709.
Adhi M, Read SP, Liu JJ, Fujimoto JG, Duker JS. High‐speed ultrahigh‐resolution OCT of Bruch's membrane in membranoproliferative glomerulonephritis type 2. Ophthalmic Surg Lasers Imaging Retina. 2014;45(6):614‐617.
Bermejo S, González E, López‐Revuelta K, et al. The coexistence of diabetic retinopathy and diabetic nephropathy is associated with worse kidney outcomes. Clin Kidney J. 2023;16(10):1656‐1663.
Bodaghi B, Massamba N, Izzedine H. The eye: a window on kidney diseases. Clin Kidney J. 2014;7(4):337‐338.
Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin‐angiotensin‐aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl. 2005;99:S57‐S65.
Ma TK, Kam KK, Yan BP, Lam YY. Renin‐angiotensin‐aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160(6):1273‐1292.
Griendling KK, Ushio‐Fukai M, Lassègue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle. Hypertension. 1997;29(1):366‐370.
St Paul A, Corbett CB, Okune R, Autieri MV. Angiotensin II, hypercholesterolemia, and vascular smooth muscle cells: a perfect trio for vascular pathology. Int J Mol Sci. 2020;21(12):4525.
Brown IAM, Diederich L, Good ME, et al. Vascular smooth muscle remodeling in conductive and resistance arteries in hypertension. Arterioscler Thromb Vasc Biol. 2018;38(9):1969‐1985.
Palatini P, Dorigatti F, Saladini F, et al. Factors associated with glomerular Hyperfiltration in the early stage of hypertension. Am J Hypertens. 2012;25(9):1011‐1016.
Yamada H, Akishita M, Ito M, et al. AT2 receptor and vascular smooth muscle cell differentiation in vascular development. Hypertension. 1999;33(6):1414‐1419.
Kaschina E, Namsolleck P, Unger T. AT2 receptors in cardiovascular and renal diseases. Pharmacol Res. 2017;125:39‐47.
AlQudah M, Hale TM, Czubryt MP. Targeting the renin‐angiotensin‐aldosterone system in fibrosis. Matrix Biol. 2020;91‐92:92‐108.
Ma K, Gao W, Xu H, Liang W, Ma G. Role and mechanism of the renin‐angiotensin‐aldosterone system in the onset and development of Cardiorenal syndrome. J Renin‐Angiotensin‐Aldosterone Syst. 2022;2022:3239057.
Dudoignon E, Dépret F, Legrand M. Is the renin‐angiotensin‐aldosterone system Good for the kidney in acute settings? Nephron. 2019;143(3):179‐183.
Semba K, Namekata K, Guo X, Harada C, Harada T, Mitamura Y. Renin–angiotensin system regulates neurodegeneration in a mouse model of normal tension glaucoma. Cell Death Dis. 2014;5(7):e1333.
Pacurari M, Kafoury R, Tchounwou PB, Ndebele K. The renin‐angiotensin‐aldosterone system in vascular inflammation and remodeling. Int J Inf Secur. 2014;2014:689360.
Abid A, Khan MA, Lee B, et al. Ocular distribution of the renin‐angiotensin‐aldosterone system in the context of the SARS‐CoV‐2 pandemic. J Renin‐Angiotensin‐Aldosterone Syst. 2022;2022:9970922.
Wilkinson‐Berka JL, Suphapimol V, Jerome JR, Deliyanti D, Allingham MJ. Angiotensin II and aldosterone in retinal vasculopathy and inflammation. Exp Eye Res. 2019;187:107766.
Higashide T, Hirooka K, Kometani M, Sugiyama K. Aldosterone as a possible contributor to eye diseases. Endocrinology. 2022;164(2):bqac201.
Coughlin BA, Feenstra DJ, Mohr S. Muller cells and diabetic retinopathy. Vis Res. 2017;139:93‐100.
Yang S, Qi S, Wang C. The role of retinal Muller cells in diabetic retinopathy and related therapeutic advances. Front Cell Dev Biol. 2022;10:1047487.
Beuse A, Deissler HL, Hollborn M, Unterlauft JD, Busch C, Rehak M. Different responses of the MIO‐M1 Mueller cell line to angiotensin II under hyperglycemic or hypoxic conditions. Biomed Rep. 2023;19(3):62.
Namekata K, Kimura A, Kawamura K, et al. Dock3 attenuates neural cell death due to NMDA neurotoxicity and oxidative stress in a mouse model of normal tension glaucoma. Cell Death Differ. 2013;20(9):1250‐1256.
Seki M, Lipton SA. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma. Prog Brain Res. 2008;173:495‐510.
Hirooka K, Kiuchi Y. The retinal renin‐angiotensin‐aldosterone system: implications for glaucoma. Antioxidants (Basel). 2022;11(4):610.
Kang S, Larbi D, Andrade M, Reardon S, Reh TA, Wohl SG. A comparative analysis of reactive Muller glia gene expression after light damage and microRNA‐depleted Muller glia‐focus on microRNAs. Front Cell Dev Biol. 2020;8:620459.
Jiang W, He S, Liu L, et al. New insights on the role of microRNAs in retinal Muller glial cell function. Br J Ophthalmol. 2024;108(3):329‐335.
Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122(7):2672‐2679.
Zhao M, Valamanesh F, Celerier I, et al. The neuroretina is a novel mineralocorticoid target: aldosterone up‐regulates ion and water channels in Müller glial cells. FASEB J. 2010;24(9):3405‐3415.
Alrashdi SF, Deliyanti D, Talia DM, Wilkinson‐Berka JL. Endothelin‐2 injures the blood‐retinal barrier and macroglial Müller cells: interactions with angiotensin II, aldosterone, and NADPH oxidase. Am J Pathol. 2018;188(3):805‐817.
Liu K, Zou H, Fan H, et al. The role of aldosterone in the pathogenesis of diabetic retinopathy. Front Endocrinol (Lausanne). 2023;14:1163787.
Canonica J, Mehanna C, Bonnard B, et al. Effect of acute and chronic aldosterone exposure on the retinal pigment epithelium‐choroid complex in rodents. Exp Eye Res. 2019;187:107747.
Allingham MJ, Tserentsoodol N, Saloupis P, Mettu PS, Cousins SW. Aldosterone exposure causes increased retinal edema and severe retinopathy following laser‐induced retinal vein occlusion in mice. Invest Ophthalmol Vis Sci. 2018;59(8):3355‐3365.
Vaajanen A, Vapaatalo H. Local ocular renin‐angiotensin system—a target for glaucoma therapy? Basic Clin Pharmacol Toxicol. 2011;109(4):217‐224.
Holappa M, Vapaatalo H, Vaajanen A. Local ocular renin‐angiotensin‐aldosterone system: any connection with intraocular pressure? A Comprehensive Review Ann Med. 2020;52(5):191‐206.
Agarwal P, Agarwal R. Trabecular meshwork ECM remodeling in glaucoma: could RAS be a target? Expert Opin Ther Targets. 2018;22(7):629‐638.
Shen F, Zhang L, Liu T. Effects of angiotensin II on the 3H‐TdR incorporation and synthesis of collagen in cultured bovine trabecular meshwork cells. Yan Ke Xue Bao. 2001;17(4):209‐212.
Dai Z, Zhang X. Pathophysiology and clinical impacts of chronic kidney disease on coronary artery calcification. J Cardiovasc Dev Dis. 2023;10(5):207.
Gao Z, Chen X. Fatty acid β‐oxidation in kidney diseases: perspectives on pathophysiological mechanisms and therapeutic opportunities. Front Pharmacol. 2022;13:805281.
Gyurászová M, Gurecká R, Bábíčková J, Tóthová Ľ. Oxidative stress in the pathophysiology of kidney disease: implications for noninvasive monitoring and identification of biomarkers. Oxidative Med Cell Longev. 2020;2020:5478708.
Zoccali C, Mallamaci F, Halimi JM, et al. Chronic cardiovascular‐kidney disorder: a new conceptual framework. Nat Rev Nephrol. 2024;20(4):201‐202.
Hernanz R, Martínez‐Revelles S, Palacios R, et al. Toll‐like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II‐induced hypertension. Br J Pharmacol. 2015;172(12):3159‐3176.
Bundy K, Boone J, Simpson CL. Wnt signaling in vascular calcification. Front Cardiovasc Med. 2021;8:708470.
Jaminon A, Reesink K, Kroon A, Schurgers L. The role of vascular smooth muscle cells in arterial remodeling: focus on calcification‐related processes. Int J Mol Sci. 2019;20(22):5694.
Hwang HS, Kim SY, Hong YA, et al. Clinical impact of coexisting retinopathy and vascular calcification on chronic kidney disease progression and cardiovascular events. Nutr Metab Cardiovasc Dis. 2016;26(7):590‐596.
Wong TY, Cheung N, Islam FM, et al. Relation of retinopathy to coronary artery calcification: the multi‐ethnic study of atherosclerosis. Am J Epidemiol. 2008;167(1):51‐58.
Naranjo A, Rayess N, Ryan E, Iv M, Mahajan VB. Retinal artery and vein occlusion in calciphylaxis. Am J Ophthalmol Case Rep. 2022;26:101433.
Cherayil NR, Scoles D, Moran AM, Elder DE, Tamhankar MA. Gazing into the crystal ball: Calciphylaxis causing striking retinal vascular calcification, ocular ischemic syndrome, crystalline retinopathy, and ischemic optic neuropathy. J Neuroophthalmol. 2021;41(2):e212‐e214.
Mishra C, Kannan NB, Chakrabarti A, Kumar M, Ramasamy K. Retinal arteriolar calcification and ischemic retinopathy in a patient with chronic kidney disease. Indian J Ophthalmol—Case Rep. 2021;1(2):337‐339.
Mason RH, Minaker SA, Lahaie Luna G, et al. Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta‐analysis. Eye (Lond). 2022.
Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19(4):942.
Wu H, Hwang DK, Song X, Tao Y. Association between aqueous cytokines and diabetic retinopathy stage. J Ophthalmol. 2017;2017:9402198.
Hang H, Yuan S, Yang Q, Yuan D, Liu Q. Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy. Mol Vis. 2014;20:1137‐1145.
Vujosevic S, Micera A, Bini S, Berton M, Esposito G, Midena E. Proteome analysis of retinal glia cells‐related inflammatory cytokines in the aqueous humour of diabetic patients. Acta Ophthalmol. 2016;94(1):56‐64.
Adamiec‐Mroczek J, Oficjalska‐Młyńczak J, Misiuk‐Hojło M. Proliferative diabetic retinopathy‐the influence of diabetes control on the activation of the intraocular molecule system. Diabetes Res Clin Pract. 2009;84(1):46‐50.
Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005;112(5):806‐816.
Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium‐derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2006;113(2):294‐301.
Mack HG, Savige J. Chronic kidney disease and cataract: seeing the light. Am J Nephrol. 2017;45(6):522‐523.
Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta‐analysis. Ophthalmology. 2014;121(11):2081‐2090.
Wang TJ, Wu CK, Hu CC, Keller JJ, Lin HC. Increased risk of co‐morbid eye disease in patients with chronic renal failure: a population‐based study. Ophthalmic Epidemiol. 2012;19(3):137‐143.
Ro JS, Moon JY, Park TK, Lee SH. Association between chronic kidney disease and open‐angle glaucoma in South Korea: a 12‐year nationwide retrospective cohort study. Sci Rep. 2022;12(1):3423.
Cho HK, Han JC, Choi JA, Chae JE, Kim RB. Association between chronic renal disease and the risk of glaucoma development: a 12‐year Nationwide cohort Study. Invest Ophthalmol Vis Sci. 2021;62(6):27.
Zhu Z, Liao H, Wang W, Scheetz J, Zhang J, He M. Visual impairment and major eye diseases in chronic kidney disease: the National Health and Nutrition Examination Survey, 2005–2008. Am J Ophthalmol. 2020;213:24‐33.
Park SJ, Byun SJ, Park JY, Kim M. Primary open‐angle glaucoma and increased risk of chronic kidney disease. J Glaucoma. 2019;28(12):1067‐1073.
Chou CL, Hsieh TC, Chen JS, Fang TC. Risks of all‐cause mortality and major kidney events in patients with new‐onset primary open‐angle glaucoma: a nationwide long‐term cohort study in Taiwan. BMJ Open. 2018;8(3):e021270.
Lim ZW, Chee ML, Thakur S, et al. Albuminuria and primary open‐angle glaucoma: the Singapore Chinese Eye Study (SCES). Br J Ophthalmol. 2021;105(5):669‐673.
Kim GA, Park SH, Ko J, et al. Albuminuria is associated with open‐angle glaucoma in nondiabetic Korean subjects: a cross‐sectional Study. PLoS One. 2016;11(12):e0168682.
Shim SH, Sung KC, Kim JM, et al. Association between renal function and open‐angle glaucoma: the Korea National Health and Nutrition Examination Survey 2010‐2011. Ophthalmology. 2016;123(9):1981‐1988.
Liu W, Guo R, Huang D, et al. Co‐occurrence of chronic kidney disease and glaucoma: epidemiology and etiological mechanisms. Surv Ophthalmol. 2023;68(1):1‐16.
Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye vis (Lond). 2015;2:17.
Grunwald JE, Alexander J, Ying GS, et al. Retinopathy and chronic kidney disease in the chronic renal insufficiency cohort (CRIC) study. Arch Ophthalmol. 2012;130(9):1136‐1144.
Kofoed‐Enevoldsen A, Jensen T, Borch‐Johnsen K, Deckert T. Incidence of retinopathy in type I (insulin‐dependent) diabetes: association with clinical nephropathy. J Diabet Complications. 1987;1(3):96‐99.
Wong TY, Coresh J, Klein R, et al. Retinal microvascular abnormalities and renal dysfunction: the atherosclerosis risk in communities study. J Am Soc Nephrol. 2004;15(9):2469‐2476.
Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381‐389.
Yip W, Ong PG, Teo BW, et al. Retinal vascular imaging markers and incident chronic kidney disease: a prospective cohort Study. Sci Rep. 2017;7(1):9374.
Edwards MS, Wilson DB, Craven TE, et al. Associations between retinal microvascular abnormalities and declining renal function in the elderly population: the cardiovascular health Study. Am J Kidney Dis. 2005;46(2):214‐224.
Sabanayagam C, Shankar A, Klein BE, et al. Bidirectional association of retinal vessel diameters and estimated GFR decline: the beaver Dam CKD Study. Am J Kidney Dis. 2011;57(5):682‐691.
Grunwald JE, Pistilli M, Ying GS, et al. Retinopathy and progression of CKD: the CRIC study. Clin J Am Soc Nephrol. 2014;9(7):1217‐1224.
Sasso FC, Pafundi PC, Gelso A, et al. Relationship between albuminuric CKD and diabetic retinopathy in a real‐world setting of type 2 diabetes: findings from No blind study. Nutr Metab Cardiovasc Dis. 2019;29(9):923‐930.
Guo X, Zhu Z, Bulloch G, Huang W, Wang W. Impacts of chronic kidney disease on retinal neurodegeneration: a cross‐cohort analysis. Am J Ophthalmol. 2024;258:173‐182.
Pugliese G, Solini A, Bonora E, et al. Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross‐sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol. 2014;13:59.
Liew G, Mitchell P, Wong TY, Wang JJ. Retinal microvascular signs are associated with chronic kidney disease in persons with and without diabetes. Kidney Blood Press Res. 2012;35(6):589‐594.
Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477‐485.
Liew G, Mitchell P, Wong TY, Iyengar SK, Wang JJ. CKD increases the risk of age‐related macular degeneration. J Am Soc Nephrol. 2008;19(4):806‐811.
Chen CY, Dai CS, Lee CC, et al. Association between macular degeneration and mild to moderate chronic kidney disease: a nationwide population‐based study. Medicine (Baltimore). 2017;96(11):e6405.
Huang CY, Lee JI, Chang CW, et al. Chronic kidney disease and its association with cataracts‐a cross‐sectional and longitudinal study. Front Public Health. 2022;10:1029962.
Huynh SC, Kifley A, Strippoli GF, Mitchell P. Is renal impairment a predictor of the incidence of cataract or cataract surgery?Findings from a population‐based study. Ophthalmology. 2005;112(2):293‐300.
Liu YT, Hung TY, Lee YK, Huang MY, Hsu CY, Su YC. Association between chronic kidney disease and risk of cataract: a Nationwide retrospective cohort Study. Am J Nephrol. 2017;45(6):524‐531.
Weiner DE, Tighiouart H, Reynolds R, Seddon JM. Kidney function, albuminuria and age‐related macular degeneration in NHANES III. Nephrol Dial Transplant. 2011;26(10):3159‐3165.
Klein R, Knudtson MD, Lee KE, Klein BE. Serum cystatin C level, kidney disease markers, and incidence of age‐related macular degeneration: the beaver dam eye Study. Arch Ophthalmol. 2009;127(2):193‐199.
Friedman E. The role of the atherosclerotic process in the pathogenesis of age‐related macular degeneration. Am J Ophthalmol. 2000;130(5):658‐663.
GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the global burden of disease Study. Lancet Glob Health. 2021;9(2):e144‐e160.
Chang JR, Koo E, Agrón E, et al. Risk factors associated with incident cataracts and cataract surgery in the age‐related eye disease Study (AREDS): AREDS report number 32. Ophthalmology. 2011;118(11):2113‐2119.
Klein BE, Klein R, Lee KE. Renal function abnormalities and incident cataract after a five‐year interval: the Beaver Dam Eye Study. Curr Eye Res. 1998;17(7):720‐725.
Berlyne GM, Ari JB, Danovitch GM, Blumenthal M. Cataracts of chronic renal failure. Lancet. 1972;1(7749):509‐511.
Nagaraj RH, Linetsky M, Stitt AW. The pathogenic role of Maillard reaction in the aging eye. Amino Acids. 2012;42(4):1205‐1220.
Winkelmayer WC, Eigner M, Berger O, Grisold W, Leithner C. Optic neuropathy in uremia: an interdisciplinary emergency. Am J Kidney Dis. 2001;37(3):E23.
Knox DL, Hanneken AM, Hollows FC, Miller NR, Schick HL Jr, Gonzales WL. Uremic optic neuropathy. Arch Ophthalmol. 1988;106(1):50‐54.
Seo JW, Jeon DH, Kang Y, et al. A case of end‐stage renal disease initially manifested with visual loss caused by uremic optic neuropathy. Hemodial Int. 2011;15(3):395‐398.
Korzets Z, Zeltzer E, Rathaus M, Manor R, Bernheim J. Uremic optic neuropathy.A uremic manifestation mandating dialysis. Am J Nephrol. 1998;18(3):240‐242.
Yau JW, Xie J, Kawasaki R, et al. Retinal arteriolar narrowing and subsequent development of CKD stage 3: the multi‐ethnic Study of atherosclerosis (MESA). Am J Kidney Dis. 2011;58(1):39‐46.